Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David J. Moss
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 0.94
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.55
Financials
Revenue
$0.00-100.0%Net Income
$-4.72MEBITDA
$-4.72MFree Cash Flow
$-3.39MEPS (diluted)
$-0.17Shares Outstanding (diluted)
27.81M+456.1%Operating Expenses
$5.01MCash & Debt
$16.33MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $50.0K | $-45.93M | $-1.86 |
| 2024 | $14.0K | $-42.08M | $-2.11 |
| 2023 | $155.0K | $-30.01M | $-1.67 |
| 2022 | $374.0K | $-27.30M | $-1.52 |
| 2021 | $181.0K | $-30.34M | $-1.88 |
| 2020 | $11.0K | $-12.10M | $-1.01 |
| 2019 | $0.00 | $-7.68M | $-0.89 |
| 2018 | $0.00 | $-12.44M | $-1.11 |
| 2017 | $0.00 | $-831.0K | $-0.07 |
| 2016 | $0.00 | $-277.0K | $-0.05 |
| 2015 | $0.00 | $-48.9K | $-0.01 |
Valuation
INMBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-11.76%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·14d ago·Neutral
INmune Bio Inc. (INMB) Q3 2026 Earnings Call Prepared Remarks Transcript INmune Bio Inc. ( INMB ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Daniel Carlson - Head of Investor Relations David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Alex Hersham Presentation Operator Greetings, an…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
…ay, November 5th Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5th, 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update. Conference Call Information To participa…
View source ↗ - Newsglobenewswire.com·25d ago·Negative
…ces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private place…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dy…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
INmune Bio to Attend the 2026 Maxim Growth Summit BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and …
View source ↗ - Newsseekingalpha.com·86d ago·Positive
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Ph
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.21 per share
Typical surprise +18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.17 vs $-0.15miss
- Thu, Aug 6$-0.05 vs $-0.21beat
- Thu, May 7$-0.20 vs $-0.24beat
- Mon, Mar 30$-0.18 vs $-0.27beat
- Thu, Oct 30$-0.24 vs $-0.31beat
- Thu, Aug 7$-1.05 vs $-0.37miss
Estimates and results for INMB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INMB officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INMB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
